The role of natural killer cells in chronic myeloid leukemia

Detalhes bibliográficos
Autor(a) principal: Danier,Anna Carolyna Araújo
Data de Publicação: 2011
Outros Autores: Melo,Ricardo Pereira de, Napimoga,Marcelo Henrique, Laguna-Abreu,Maria Theresa Cerávolo
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Revista brasileira de hematologia e hemoterapia (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842011000300015
Resumo: Chronic myeloid leukemia is a neoplasia resulting from a translocation between chromosomes 9 and 22 producing the BCR-ABL hybrid known as the Philadelphia chromosome (Ph). In chronic myeloid leukemia a proliferation of malignant myeloid cells occurs in the bone marrow due to excessive tyrosine kinase activity. In order to maintain homeostasis, natural killer cells, by means of receptors, identify the major histocompatibility complex on the surface of tumor cells and subsequently induce apoptosis. The NKG2D receptor in the natural killer cells recognizes the transmembrane proteins related to major histocompatibility complex class I chain-related genes A and B (MICA and MICB), and it is by the interaction between NKG2D and MICA that natural killer cells exert cytotoxic activity against chronic myeloid leukemia tumor cells. However, in the case of chronic exposure of the NKG2D receptor, the MICA ligand releases soluble proteins called sMICA from the tumor cell surface, which negatively modulate NKG2D and enable the tumor cells to avoid lysis mediated by the natural killer cells. Blocking the formation of sMICA may be an important antitumor strategy. Treatment using tyrosine kinase inhibitors induces modulation of NKG2DL expression, which could favor the activity of the natural killer cells. However this mechanism has not been fully described in chronic myeloid leukemia. In the present study, we analyze the role of natural killer cells to reduce proliferation and in the cellular death of tumor cells in chronic myeloid leukemia.
id ABHHTC-1_faeed31bd979acdaba0d48b38778e41e
oai_identifier_str oai:scielo:S1516-84842011000300015
network_acronym_str ABHHTC-1
network_name_str Revista brasileira de hematologia e hemoterapia (Online)
repository_id_str
spelling The role of natural killer cells in chronic myeloid leukemiaLeukemia, myelogenous, chronic, BCR-ABL PositiveKiller cells, naturalkiller cell lectin-like receptor subfamily DProtein kinase inhibitors/pharmacologyChronic myeloid leukemia is a neoplasia resulting from a translocation between chromosomes 9 and 22 producing the BCR-ABL hybrid known as the Philadelphia chromosome (Ph). In chronic myeloid leukemia a proliferation of malignant myeloid cells occurs in the bone marrow due to excessive tyrosine kinase activity. In order to maintain homeostasis, natural killer cells, by means of receptors, identify the major histocompatibility complex on the surface of tumor cells and subsequently induce apoptosis. The NKG2D receptor in the natural killer cells recognizes the transmembrane proteins related to major histocompatibility complex class I chain-related genes A and B (MICA and MICB), and it is by the interaction between NKG2D and MICA that natural killer cells exert cytotoxic activity against chronic myeloid leukemia tumor cells. However, in the case of chronic exposure of the NKG2D receptor, the MICA ligand releases soluble proteins called sMICA from the tumor cell surface, which negatively modulate NKG2D and enable the tumor cells to avoid lysis mediated by the natural killer cells. Blocking the formation of sMICA may be an important antitumor strategy. Treatment using tyrosine kinase inhibitors induces modulation of NKG2DL expression, which could favor the activity of the natural killer cells. However this mechanism has not been fully described in chronic myeloid leukemia. In the present study, we analyze the role of natural killer cells to reduce proliferation and in the cellular death of tumor cells in chronic myeloid leukemia.Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular2011-06-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842011000300015Revista Brasileira de Hematologia e Hemoterapia v.33 n.3 2011reponame:Revista brasileira de hematologia e hemoterapia (Online)instname:Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)instacron:ABHHTC10.5581/1516-8484.20110057info:eu-repo/semantics/openAccessDanier,Anna Carolyna AraújoMelo,Ricardo Pereira deNapimoga,Marcelo HenriqueLaguna-Abreu,Maria Theresa Cerávoloeng2011-07-27T00:00:00Zoai:scielo:S1516-84842011000300015Revistahttp://www.rbhh.org/pt/archivo/https://old.scielo.br/oai/scielo-oai.phpsbhh@terra.com.br||secretaria@rbhh.org1806-08701516-8484opendoar:2011-07-27T00:00Revista brasileira de hematologia e hemoterapia (Online) - Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)false
dc.title.none.fl_str_mv The role of natural killer cells in chronic myeloid leukemia
title The role of natural killer cells in chronic myeloid leukemia
spellingShingle The role of natural killer cells in chronic myeloid leukemia
Danier,Anna Carolyna Araújo
Leukemia, myelogenous, chronic, BCR-ABL Positive
Killer cells, natural
killer cell lectin-like receptor subfamily D
Protein kinase inhibitors/pharmacology
title_short The role of natural killer cells in chronic myeloid leukemia
title_full The role of natural killer cells in chronic myeloid leukemia
title_fullStr The role of natural killer cells in chronic myeloid leukemia
title_full_unstemmed The role of natural killer cells in chronic myeloid leukemia
title_sort The role of natural killer cells in chronic myeloid leukemia
author Danier,Anna Carolyna Araújo
author_facet Danier,Anna Carolyna Araújo
Melo,Ricardo Pereira de
Napimoga,Marcelo Henrique
Laguna-Abreu,Maria Theresa Cerávolo
author_role author
author2 Melo,Ricardo Pereira de
Napimoga,Marcelo Henrique
Laguna-Abreu,Maria Theresa Cerávolo
author2_role author
author
author
dc.contributor.author.fl_str_mv Danier,Anna Carolyna Araújo
Melo,Ricardo Pereira de
Napimoga,Marcelo Henrique
Laguna-Abreu,Maria Theresa Cerávolo
dc.subject.por.fl_str_mv Leukemia, myelogenous, chronic, BCR-ABL Positive
Killer cells, natural
killer cell lectin-like receptor subfamily D
Protein kinase inhibitors/pharmacology
topic Leukemia, myelogenous, chronic, BCR-ABL Positive
Killer cells, natural
killer cell lectin-like receptor subfamily D
Protein kinase inhibitors/pharmacology
description Chronic myeloid leukemia is a neoplasia resulting from a translocation between chromosomes 9 and 22 producing the BCR-ABL hybrid known as the Philadelphia chromosome (Ph). In chronic myeloid leukemia a proliferation of malignant myeloid cells occurs in the bone marrow due to excessive tyrosine kinase activity. In order to maintain homeostasis, natural killer cells, by means of receptors, identify the major histocompatibility complex on the surface of tumor cells and subsequently induce apoptosis. The NKG2D receptor in the natural killer cells recognizes the transmembrane proteins related to major histocompatibility complex class I chain-related genes A and B (MICA and MICB), and it is by the interaction between NKG2D and MICA that natural killer cells exert cytotoxic activity against chronic myeloid leukemia tumor cells. However, in the case of chronic exposure of the NKG2D receptor, the MICA ligand releases soluble proteins called sMICA from the tumor cell surface, which negatively modulate NKG2D and enable the tumor cells to avoid lysis mediated by the natural killer cells. Blocking the formation of sMICA may be an important antitumor strategy. Treatment using tyrosine kinase inhibitors induces modulation of NKG2DL expression, which could favor the activity of the natural killer cells. However this mechanism has not been fully described in chronic myeloid leukemia. In the present study, we analyze the role of natural killer cells to reduce proliferation and in the cellular death of tumor cells in chronic myeloid leukemia.
publishDate 2011
dc.date.none.fl_str_mv 2011-06-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842011000300015
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842011000300015
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.5581/1516-8484.20110057
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular
publisher.none.fl_str_mv Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular
dc.source.none.fl_str_mv Revista Brasileira de Hematologia e Hemoterapia v.33 n.3 2011
reponame:Revista brasileira de hematologia e hemoterapia (Online)
instname:Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)
instacron:ABHHTC
instname_str Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)
instacron_str ABHHTC
institution ABHHTC
reponame_str Revista brasileira de hematologia e hemoterapia (Online)
collection Revista brasileira de hematologia e hemoterapia (Online)
repository.name.fl_str_mv Revista brasileira de hematologia e hemoterapia (Online) - Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)
repository.mail.fl_str_mv sbhh@terra.com.br||secretaria@rbhh.org
_version_ 1754213111214112768